$A

Agilent earnings analysis: questions answered and next catalysts

Agilent reported FY2026 Q3 earnings with EPS of $1.62 (8.7% above consensus) and revenue of $1.88B (2.2% above estimates). This marks the third consecutive quarter of EPS acceleration, with revenue growth of 6.7% in FY2025. However, gross margins slipped to 52.4% and free cash flow declined to $1.15B. The stock trades at 30.9x trailing P/E, with a fair-value estimate of $145.64, suggesting a 7.6% overvaluation.

Original reporting
Published Aug 27, 2026, 5:58 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 6:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$A
Bullish
high confidence
Mentioned
$A
Relevance
8/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$ABullishHigh
01

Why it matters

The earnings beat reinforces the recovery narrative but raises questions on margin sustainability, which could influence investor positioning in the sector.

02

Market read

Fresh earnings data for a large‑cap biotech equipment maker; likely short‑term price movement and sector‑wide sentiment effect.

03

What to watch

Potential impact of upcoming FY2026 Q4 guidance and FY2027 outlook on valuation; macro AI spending trends could alter growth trajectory.

Relevance 8/10Novelty 8/10Timing: after‑hours Aug 26 release

Background

Agilent's earnings come amid a broader tech rally driven by Nvidia's results, with the Nasdaq up >1%. The company is positioned as a supplier of analytical instruments to the life‑science market.

Company-level read

Ticker impact

$ABullishHigh confidence
Context

Agilent reported FY2026 Q3 earnings beat with EPS $1.62 (+8.7%) and revenue $1.88B (+2.2%) after hours on Aug 26.

Expected impact

Potential 3‑5% upside in the next trading session if margins improve; downside risk if margin issues persist.

Evidence & confidence

The beat is fresh primary data for a large‑cap stock, and the market has already rewarded the prior quarter (+17.6%).

Market effects

Signals continued recovery in the life‑science instrumentation sector, supporting peers with similar exposure.

U.S. biotech and diagnostics stocks may see modest gains as earnings beat reinforces sector momentum.

Highlights resilience of U.S. tech‑enabled health‑care companies amid broader market AI enthusiasm.

Counterpoint

Margin compression and falling free cash flow could lead to a pull‑back if investors demand profitability over growth.

Key entities

  • Agilent Technologies Inc

    Life‑science and diagnostics instrumentation provider.

Related articles

$AHighAI 8/10

Agilent Technologies Inc (A) (Q3 2026) Earnings Call Highlights: Strong Core Growth

Agilent Technologies reported Q3 2026 earnings, raising guidance but noting a slowdown in core growth to 5.2%-6.2% in Q4. Diagnostics grew 6%, below expectations, while China grew 9%, driven by pharma and biotech. The company faces inflationary pressures but expects mid-teens growth in specialty CDMO. Management reaffirmed a $1 billion reshoring opportunity by 2030. Margins are expected to expand over 100 basis points ex-tariff refunds.

$AHighAI 8/10

Agilent Q3 earnings beat sends shares to 20-day high

Agilent Technologies reported Q3 revenue of $1.88bn, beating guidance and lifting shares to a 20-day high. Operating margin was 27.2%, with EPS of $1.56. Pharma revenue rose 12%, and China sales grew 9%. The company raised its full-year revenue growth outlook to 5.8% to 6%.

$NVDAHighAI 8/10

Stocks making the biggest moves after hours: Nvidia, Salesforce, CrowdStrike, Urban Outfitters and more

Nvidia, Salesforce, Okta, Agilent, CrowdStrike, Everpure, Veeva, Urban Outfitters, and Synopsys reported earnings. Nvidia, Salesforce, Okta, Agilent, CrowdStrike, Everpure, and Veeva exceeded expectations, while Urban Outfitters met estimates and Synopsys fell. Nvidia reported $2.22 EPS and $96.22B revenue, raising Q3 guidance to $108B. Salesforce reported $11.35B revenue and $5.90 EPS. Okta raised full-year guidance. Synopsys raised annual revenue and profit forecasts but shares fell 2%.